Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry News Roundup

This article was originally published in The Tan Sheet

Executive Summary

Prestige international sales jump; P&G settles Whitestrips infringement case; BlueOcean targets Indian omega-3 market; ViaDerma shop its dual carrier transdermal delivery; unapproved drugs make prostate, rosacea claims; and more industry news.

You may also be interested in...



Supplement Firms Launch New Brands, But Charged With Same Violations By FTC

Firms allegedly made false claims for four products labeled as supplements they launched since 2018 settlement. “Brazenly ignoring the Court’s order barring them from making unsubstantiated claims,” firms “have continued promoting their products with outrageous claims,” FTC contends.

'Free Trial' Plus False Claims Equals More FTC Enforcement In Supplement Market

FTC on consecutive days announced court order closing a California business allegedly charging consumers for products and enrolling them in negative-option continuity plans without their consent after they responded to bogus free trial online offers, and started mailing 16,596 checks totaling more than $750,000 to consumers who bought deceptively marketed supplements from a Maine firm that also lured customers with a free trial pitch.

FTC Curbs Another 'Free' Ride: Health And Wellness Industry News

Health Research Laboratories agrees to settle an FTC complaint alleging false "free" offers on top of bogus health claims; reports that biotin can interfere with certain lab tests are reminders for consumers to tell doctors about supplements they use, says CRN; kratom group asks FDA and states "to tone down their overheated rhetoric about the non-opiate botanical"; and health and wellness recalls.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel